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Background and Purpose—Evidence of drug efficacy in vascular dementia (VaD) is scanty. Therapeutic trials should
address VaD subtypes. We studied the efficacy and safety of the calcium antagonist nimodipine in subcortical VaD.
Methods—242 patients defined as affected by subcortical VaD based on clinical (ICD-10) and computed tomography
criteria were randomized to oral nimodipine 90 mg/d or placebo.
Results—230 patients (121 nimodipine, mean age 75.26.1; 109 placebo, 75.46.0) were valid for the intention-to-treat
analysis. At 52 weeks, the Sandoz Clinical Assessment Geriatric scale 5-point variation (primary outcome measure) did
not differ significantly between the 2 groups. However, patients on nimodipine performed better than placebo patients
in lexical production (P0.01) and less frequently showed deterioration (3 or more point-drop versus baseline) on a
Mini-Mental State Examination (28.1% versus 50.5%; 2 P0.01) and Global Deterioration Scale (P0.05). Dropouts
and adverse events were all significantly more common among placebo than nimodipine patients, particularly
cardiovascular (30 versus 13; RR, 2.26; 95% CI, 1.11 to 4.60) and cerebrovascular events (28 versus 10; RR, 2.48; 95%
CI, 1.23 to 4.98), and behavioral disturbances requiring intervention (22 versus 5; RR, 3.88; 95% CI, 1.49 to 10.12). A
worst-rank analysis, performed to correct for the effect of the high dropout rate in the placebo group, showed additional
significant differences in favor of nimodipine in Set Test and MMSE total scores.
Conclusions—Nimodipine may be of some benefit in subcortical VaD. Confirming previous results, the safety analysis of
this study shows that in this high-risk population, nimodipine might protect against cardiovascular comorbidities.
(Stroke. 2005;36:619-624.)
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Vascular dementia (VaD) is a common type of dementiabut current therapeutic options are scarce. Under the
term VaD, various conditions with considerably different
pathophysiological mechanisms are included, and therapeutic
choices in VaD should focus on specific subtypes.1 Subcor-
tical VaD is likely the most frequent VaD subtype and has a
rather homogeneous clinical, radiological, and pathological
picture.2,3 The dihydropyridinic calcium antagonist nimodip-
ine has been proposed as a drug able to improve cognition in
VaD because of vasoactive and neuroprotective actions.4 Its
effect on age-related microangiopathy in experimental mod-
els5 makes nimodipine of potential interest for the treatment
of small-vessel VaD subtypes. After the results of an open-
label study6 and a post-hoc analysis of a randomized trial,7
both showing some beneficial effects of nimodipine in
patients with subcortical VaD features, an ad hoc designed
trial was conducted to further test the efficacy and safety of
oral nimodipine in subcortical VaD.
Materials and Methods
Study Design
This was an explorative multicenter, randomized, double-blind,
placebo-controlled trial conducted between December 1996 and
February 2002. The aim was to investigate the efficacy and safety of
oral nimodipine in patients defined as affected by subcortical VaD
based on ICD-10 criteria corroborated by neuroimaging criteria.
The patients underwent a 4-week, single-blinded placebo run-in
period before being randomized to receive either 330 mg nimo-
dipine or matching placebo tablets per day for 52 weeks. The study
was performed under the good clinical practice regulations and
according to the Declaration of Helsinki. The protocol and the
information for the patients and caregivers were approved by each
center local ethic committee. A review committee formed by the
principal investigators, independent clinicians, and biostatisticians
performed preplanned blind reviews and monitored the study course.
Study Patients
Inclusion criteria included ICD-10 criteria for subcortical VaD
(dementia, hypertension, and evidence of vascular disease in the
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cerebral hemispheric deep white matter with cortical preservation)8;
dementia syndrome for 6 months and 3 years, mild-to-moderate
severity as defined by a Mini-Mental State Examination (MMSE)9
score 12 and 24, and a Global Deterioration Score10 3 and 5;
computed tomography scan performed not 3 months before base-
line showing white matter changes of severe degree, ie, extending to
the centrum semiovale (corresponding to grade 2 of van Swieten et
al’s scale11) and at least 1 definite image consistent with a lacunar
infarct. These criteria were checked centrally before randomization
by a single observer who, examining the scan of each candidate
patient, adjudicated cases for enrollment. No new cerebrovascular
event had to occur between computed tomography scanning and the
baseline visit. Inclusion criteria also included age between 55 and 87
years; Hachinski ischemic score 412; expected good compliance to
study medication and protocol; and informed written consent.
Exclusion criteria were: (1) past diagnosis of major depression,
schizophrenia, major anxiety syndrome, or manic–depressive ill-
ness; (2) Alzheimer disease as defined using the National Institute of
Neurological and Communicative Disorders and Stroke/Alzheimer’s
Disease and Related Disorders Association criteria,13 Parkinson
disease, Huntington disease, and fronto-temporal dementia; (3) other
diseases known to cause dementia (eg, central nervous system
trauma, tumor or infections, normal pressure hydrocephalus, meta-
bolic disorders, folic acid, vitamin B12, or thyroid hormone defi-
ciency; (4) contraindications to dihydropyridine derivatives; (5)
medical conditions expected to progress, recur, or change to such a
degree to interfere with the assessment of the clinical and mental
status; (6) clinically relevant cardiac or pulmonary insufficiency; (7)
relevant electrocardiograph abnormalities; bradycardia (50 bpm)
or tachycardia (120 bpm) under resting conditions; (9) myocardial
infarction within the past 6 months; (10) stroke still requiring
neurological rehabilitation; (11) severe/untreated blood pressure
(systolic 180 mm Hg, diastolic 95 mm Hg); clinically relevant
liver function impairment; (13) insulin-dependent diabetes mellitus;
(14) idiopathic epilepsy and anti-epileptic treatment; (15) severe
anemia (Hb 10 mg/dL); (16) severe gastrointestinal disease; and
(17) cancer.
The intake of cerebral vasodilators, nootropic agents, and pentoxi-
fyllin was not allowed. Other psychotropic drugs were allowed if
started 3 or more months before the inclusion in the study and the
dose was expected to be stable during the whole double-blind phase.
Angiotensin-converting enzyme inhibitors, diuretics, -blockers,
verapamil, or diltiazem were allowed if the treatment had been
initiated at least 6 weeks before inclusion. Permitted were also
short-acting benzodiazepines, anti-arrhythmics, or antithrombotics.
Before the inclusion, all patient data were reviewed under blind
conditions by the review committee to verify inclusion/exclusion
criteria, concomitant diseases, and medications.
Efficacy Assessment
The effect of nimodipine compared with that of placebo was assessed
using the following instruments: (1) Sandoz Clinical Assessment
Geriatric (SCAG) scale,14 an inventory of 18 target symptoms
(severity of each is rated by a 7-point scale) covering 4 areas: global
cognition, mood and behavior, ability to cope with activities of daily
living, and somatic symptoms; (2) Global Deterioration Score10; (3)
Set test15 and lexical production,16 exploring semantic and phonemic
verbal fluency, respectively; (4) Digit Span17; (5) MMSE9; (6)
Zahlen-Verbindungs Test (ZVT-G)18; (7) gait performance test19; (8)
Nurses Observation Scale for Geriatric patients,20 an index of
activities of daily living; (9) the Clinical Global Impression scale21
expressed in 7 classes (marked, moderate, or slight improvement; no
effect; slight, moderate, or severe deterioration); and (10) Hamilton
Depression scale.22
The main efficacy measure was the SCAG 5-point variation
chosen on the results of the aforementioned pilot study.6 Here, in a
pilot open design, similarly defined patients were administered
nimodipine and were followed-up using similar assessment proce-
dures. After 52 weeks, treatment patients showed a 5-point change
compared with the baseline, a variation that was considered clini-
cally meaningful based on investigators’, patients’, and relatives’
judgment. All the remaining test results served as secondary mea-
sures. Safety measures included recording of adverse events, blood
pressure, cardiovascular vital signs, and laboratory data. To be
classified as severe, adverse events had to be life-threatening or
cause death, hospitalization, or prolongation of hospital stay. Other
adverse events and the introduction of new drug treatments recorded
in the case report form were checked by the monitoring agency and
finally reviewed and classified blind to the treatment group by the
review committee using the Coding Symbols for Thesaurus of
Adverse Reaction Terms terminology.23
Statistical Analyses
The needed sample size was calculated taking into account the
following assumptions and hypotheses from the previously quoted
pilot study.4,7 Considering the difference between groups by
SCAG5 points, standard deviation11 points, an overall level of
5% for a 2-sided test with a 90% power (1-), the required minimum
number of valid patients was 100 per treatment group. Given an
expected dropout of 20%, the total number of patients to be
randomized was increased to 240.
The review committee defined 3 samples of patients: (1) valid for
efficacy (or per protocol): all randomized patients with evaluation made
while on study drug at week 52; (2) intention-to-treat (ITT): patients
receiving at least 1 dose of treatment and followed-up at least once; and
(3) safety population: patients with a baseline evaluation and at least 1
dose of the tested drug. The baseline homogeneity of the treatment
groups for demographic and baseline scores was evaluated with
ANOVA for continuous variables and 2 test or Fisher exact test for
categorical ones. Efficacy analysis was planned on the per-protocol
sample using the 5-point cutoff variation. The SCAG total score was
also analyzed by groups at the end of treatment period with an
ANCOVA model, adjusting the final scores for the baseline ones. For
patients not completing the 52-week treatment, the last observation
carried forward approach was planned for the final evaluation in the ITT
analysis.
Figure 1 accounts for the disposition of all the patients. A larger
than expected number of patients discontinued, and discontinuations
occurred mostly in the placebo group. Given the significantly
unbalanced dropout rate, the results based on both the per-protocol
and the ITT samples could be too conservative relating to nimodipine
treatment and the last observation carried forward approach inade-
quate for a 1-year study of a progressive disease. Thus, besides the
conventional analyses, a nonplanned worst-rank analysis24 was
performed. In this approach, missing observations are considered
informative when they have a suspected causal association with the
patient’s underlying disease,24 a common fact in progressive dis-
eases. Each missing informative observation is replaced with a rank
score corresponding to a measurement value worse than any actually
observed score and a rank analysis is subsequently performed.
ANCOVA was used in this analysis.
Safety Analysis
The frequency of adverse events and the mean baseline and final
blood pressure values were compared by treatment group. Absolute
incidence rate of major events at 52 weeks was counted and relative
risks (RRs) were calculated between nimodipine and placebo to-
gether with 95% confidence intervals (CIs).
Results
The total number of randomized patients was 242, 124 in the
nimodipine and 118 in the placebo group. One hundred seven
patients (86.3%) in the nimodipine and 77 (65.2%) in the
placebo group completed the study (Fisher exact test
P0.0001). One hundred forty-nine patients, 94 in the
nimodipine and 55 in the placebo group, were valid for the
per-protocol analysis. Reasons for exclusion were: adverse
events (4 nimodipine, 16 placebo); not allowed medication (7
nimodipine, 15 placebo); poor compliance (5 nimodipine, 3
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placebo); consent withdrawn (7 nimodipine, 10 placebo);
protocol violation (2 nimodipine, 4 placebo); lost to
follow-up (2 nimodipine, 5 placebo); death (3 nimodipine, 7
placebo); and concomitant disease (3 placebo). Figure 1
shows timing of dropouts. A description of demographic and
baseline characteristics of the ITT population is provided in
Table 1. Physical examination alterations, history of smoking
or drug allergy, and education level were all balanced
between the groups. Use of concomitant medications at
baseline was present in almost all patients in both groups.
Efficacy Analyses
When considering the primary end point effect, ie, a SCAG
total score variation of 5 points comparing baseline versus
end of study in the per-protocol population (Table 2), wors-
ening was recorded in 13 of the 94 (13.8%) nimodipine-
treated and in 13 (23.6%) of the 55 placebo-treated patients,
a difference that was not statistically significant. Very similar
results were obtained using the ITT population. Evaluating
secondary outcome measures (Tables 3 and 4 show the results
from per protocol and ITT analyses, respectively), patients on
nimodipine performed significantly better on lexical produc-
tion than placebo patients. A similar trend, although not
statistically significant, was apparent for the Set Test.
A post-hoc analysis was also performed using different
cutoffs for the MMSE score variations. Considering sub-
groups of patients with 1-, 2-, 3-, or 4-point differences from
baseline MMSE score, the analyses gave significant results
for both 2 and 3 cutoff points, not for 1 or 4. We decided to
report the results achieved using the 3-point cutoff because
they were considered to be clinically more sound. The
proportion of patients worsening at least 3 points on MMSE
total score after treatment was significantly lower among
nimodipine (n34; 28.1%) than placebo patients (n55;
50.5%) (2 P0.01). A significant trend was also observed
for the Global Deterioration Score scale with less patients
using nimodipine (n22, 18.2%) than placebo (37, 33.9%)
being in the severe category at 52 weeks (P0.05). When the
whole data set was re-analyzed with the worst-rank approach,
some differences emerged with statistical significance:
MMSE, lexical production, and Set test scores after the
1-year duration of the study were significantly better among
patients who were treated with nimodipine (Table 4).
Safety
A total of 239 patients were valid for the safety analysis, 124
in nimodipine and 115 in placebo group. Adverse events of
any type were reported more frequently in the placebo than in
the nimodipine group (180 versus 135; RR, 1.29; 95% CI,
Figure 1. Trial profile.
TABLE 1. Demographic Characteristics of the
Intention-to-Treat Population
Nimodipine
(n121)
Placebo
(n109)
Total Sample
(n230) P *
Male, no. % 70 (58) 67 (61) 137 (60) 0.59
Age, meanSD 75.26.1 75.46.0 75.36.0 0.84
BMI, kg/m2 21.43.1 20.72.8 21.13.0 0.07
HIS 8.452.6 8.852.9 8.642.7 0.19
Disease duration, y 1.310.9 1.390.8 1.350.9 0.31
*Fisher exact test or ANOVA.
BMI indicates body mass index; HIS, Hachinski ischemic score.
TABLE 2. Proportion of Patients Showing >5-Point Change on
Sandoz Clinical Assessment Geriatric Scale
Improvement
No. (%)
No Change
No. (%)
Worsening
No. (%) Total
Nimodipine 34 (36.2) 47 (50.0) 13 (13.8) 94
Placebo 16 (29.1) 26 (47.3) 13 (23.6) 55
Total 50 (33.5) 73 (49.0) 26 (17.4) 149
2 P0.29.
Baseline vs end of study, per protocol population.
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1.03–1.61). Significantly different was also the number of
serious adverse events: 43 in the nimodipine and 66 in the
placebo group (RR, 1.58; 95% CI, 1.03–2.42). No serious
adverse event or study discontinuation was imputed to the
study drug. No clinically meaningful abnormality in blood
chemistry, urinalysis, and laboratory examinations was con-
sidered to be related to nimodipine. Mean blood pressure
values did not change throughout the study, remaining
consistent in the 2 groups (baseline: nimodipine 144/
83 mm Hg; placebo145/82; 26 weeks: nimodipine 142/81,
placebo 142/82; 52 weeks: nimodipine 143/82, placebo 144/
82). The most frequent adverse events were cardiovascular
and cerebrovascular acute events. Eleven strokes occurred, 2
in the nimodipine group (1.6%) and 9 in the placebo group
(7.8%); 10 transient ischemic attacks, 4 in the nimodipine
group (3.2%) and 6 in the placebo group (5.2%); 7 hyperten-
sive crises, all in the placebo group (6.1%); 9 myocardial
infarctions, 3 in the nimodipine group (2.4%) and 6 in the
placebo group (5.2%). Adverse events were further grouped
into cardiac, cerebrovascular, psychiatric, neurological, and
residual events (classification available on request). Com-
pared with placebo, significantly less nimodipine-treated
patients experienced cardiac, cerebrovascular, or psychiatric
events, all events, and serious events (Figure 2).
Discussion
Being the first randomized, double-blind, controlled trial
focusing on subcortical VaD, this study has to be considered
exploratory. An unblinded controlled study25 and 2 open trials
have been reported in similar patients.6,26 Although the
primary outcome measure was not significantly altered by the
active treatment, some secondary measures showed differ-
ences in favor of nimodipine, namely lexical production and
the MMSE when a substantial 3-point change cutoff to assess
improvement or worsening was used as an outcome measure.
The first of these 2 results may indicate a positive effect in the
executive function domain known to be selectively compro-
mised in subcortical VaD.2,3 The worst-rank analysis we
TABLE 3. Scores of Neuropsychological, Functional, Motor, and Depression Scales
Nimodipine
(n94) Mean (SD)
Placebo
(n55) Mean (SD)
P * (vs baseline)Baseline 52 Weeks Baseline 52 Weeks
SCAG 43.7 (13.0) 48.6 (16.4) 45.0 (12.6) 47.9 (16.1) 0.27
MMSE 20.0 (3.0) 19.2 (4.6) 20.5 (3.2) 19.1 (5.5) 0.60
Set Test 26.9 (10.5) 25.6 (11.2) 29.3 (11.8) 24.91 (11.7) 0.07
Digit Span 2.4 (1.2) 2.2 (1.3) 2.6 (1.3) 2.6 (1.4) 0.15
Lexical Production 8.6 (5.9) 8.3 (5.6) 10.5 (6.2) 8.1 (6.9) 0.01
ZVT-G (seconds) 148.0 (98.6) 139.5 (82.8) 120.1 (80.0) 121.2 (87.3) 0.75
NOSGER 68.1 (17.7) 74.8 (19.7) 68.0 (13.7) 75.6 (17.3) 0.71
Hamilton 7.9 (5.1) 8.5 (6.3) 8.3 (5.2) 8.0 (5.0) 0.38
Motor performance 10.3 (3.2) 10.1 (3.1) 10.8 (3.2) 10.5 (3.4) 0.83
*ANOVA.
MMSE indicates mini-mental state examination; SCAG, Sandoz Clinical Assessment Geriatric Scale.
Per-protocol population.
TABLE 4. Scores of Neuropsychological, Functional, Motor, and Depression Scales
Nimodipine
(n121) Mean (SD)
Placebo
(n109) Mean (SD) P (vs baseline)
Baseline 52 Weeks Baseline 52 Weeks ITT*
Worst
Rank†
SCAG 44.0 (12.8) 49.0 (16.1) 46.2 (12.7) 50.3 (16.1) 0.36 0.15
MMSE 20.1 (3.1) 19.2 (4.6) 20.0 (3.1) 18.4 (5.5) 0.10 0.01
Set Test 27.2 (10.7) 26.0 (12.4) 28.1 (12.1) 25.4 (12.8) 0.13 0.01
Digit Span 2.5 (1.3) 2.2 (1.3) 2.6 (1.5) 2.5 (1.4) 0.43 0.27
Lexical Production 8.9 (6.2) 8.7 (5.9) 9.5 (6.7) 8.1 (7.0) 0.01 0.001
ZVT-G (seconds) 142.4 (92.4) 133.6 (81.1) 131.2 (85.8) 128.9 (84.8) 0.38 n.a.
NOSGER 68.6 (18.1) 75.0 (19.8) 72.5 (16.8) 78.6 (19.4) 0.71 0.24
Hamilton 7.9 (5.3) 8.5 (6.5) 8.6 (5.5) 8.3 (5.0) 0.62 0.06
Motor performance 10.3 (3.1) 10.1 (3.2) 10.3 (3.3) 10.1 (3.5) 0.82 n.a.
*ANOVA.
†ANCOVA.
ITT and worst rank analyses.
ITT indicates intention-to-treat analysis (last observation carried forward).
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performed post-hoc to take into account the large dropout rate
observed in the placebo group improved the results of some
efficacy measures in favor of treatment with nimodipine. This
approach is based on the assumption that all the dropout
patients deteriorated, which may be not necessarily true.
However, more than half of the dropouts that occurred in the
placebo group appeared somehow related to the underlying
disease progression, eg, acute cardiovascular and cerebrovas-
cular events, acute psychiatric episodes, or death. Another
cause of dropout, ie, the introduction of not allowed medica-
tions, major sedatives necessary to control episodes of agita-
tion in most cases, can also be considered an epiphenomenon
of the underlying disease worsening.
Our study major limitation rests on the large dropout rate.
Interestingly, dropouts and adverse events occurred much
more frequently in the placebo group given the randomized
and double-blind design of the study. The significantly fewer
cardiovascular and cerebrovascular events observed in the
nimodipine group, a finding already observed in another
randomized double-blind study,27 could suggest a protective
effect of nimodipine against vascular disease progression in
this high-risk population. This effect does not seem to depend
on an antihypertensive action because blood pressure values
remained stable during the study period. Because the aim of
the study was not to test the efficacy of nimodipine in the
secondary prevention of vascular diseases, this observation
has to be taken as hypothesis-generating.
A strength of our study may be the rigorous selection of
patients. The computed tomography diagnosis of subcortical
VaD, required to complement the clinical one, was based on
strict criteria applied before randomization by 1 observer
blind to the patient clinical data. The requirement of clinical
criteria combined with neuroimaging findings of extensive
leukoaraiosis associated with lacunar infarcts is consistent
with the recently proposed criteria for subcortical VaD.2
Another study strength is the rather long duration of
follow-up under blind conditions, which was double com-
pared with other recent trials performed in VaD. It is worth
noting that in our study, the placebo group outcome was less
favorable than that shown by other recent trials in VaD,
pointing toward a more severe progression in this VaD
subtype of patients.
In conclusion, patients with subcortical VaD may benefit
from treatment with oral nimodipine, although the observa-
tions of our study need to be corroborated by a larger
controlled study.
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